NCT03517449 · ADVERSE EVENTS

Adverse events

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) · Source last updated 2026-03-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Up to approximately 79 months
Other-event reporting threshold: 5%

All-cause mortality was reported on all randomized participants. AEs were reported on participants who received atleast 1 dose of treatment. MedDRA preferred terms Neoplasm progression, Malignant neoplasm progression \& Disease progression not related to drug were excluded.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
First Course: Lenvatinib + Pembrolizumab Participants with Endometrial cancer (EC) received lenvatinib 20 milligrams (mg) orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study	237 / 406	404 / 406	317 / 406
First Course: TPC Doxorubicin or Paclitaxel Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.	121 / 388	379 / 388	362 / 388
Second Course: Lenvatinib + Pembrolizumab Eligible participants who completed the first course of up to 35 administrations of pembrolizumab (\~2 years) and lenvatinib (\~2years) or who had Stable disease (SD) or partial response (PR) or had attained complete response (CR), but experienced radiologic progression of disease (PD) initiated a second course of pembrolizumab and lenvatinib at investigators discretion at the same dose and schedule at lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle upto 17 cycles (upto \~1 year)	4 / 21	20 / 21	8 / 21
TPC Crossover Eligible participants who completed the first course of either doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle and eligible participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\^2 doxorubicin, a maximum dose of paclitaxel per standard of care or who had Stable disease (SD) or partial response (PR) or had attained complete response (CR), but experienced radiologic progression of disease (PD) initiated treatment with pembrolizumab and lenvatinib at investigators discretion at the same dose and schedule at lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle upto 17 cycles (upto \~1 year)	1 / 6	6 / 6	1 / 6

Group identifiers: EG000: First Course: Lenvatinib + Pembrolizumab · EG001: First Course: TPC Doxorubicin or Paclitaxel · EG002: Second Course: Lenvatinib + Pembrolizumab · EG003: TPC Crossover

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
9
num At Risk
388
num Events
9
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Anaemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
0
num At Risk
406
num Events
0
group Id
EG001
num Affected
1
num At Risk
388
num Events
1
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Febrile bone marrow aplasia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
2
num At Risk
406
num Events
2
group Id
EG001
num Affected
16
num At Risk
388
num Events
17
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Febrile neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
0
num At Risk
406
num Events
0
group Id
EG001
num Affected
1
num At Risk
388
num Events
1
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Leukocytosis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
0
num At Risk
406
num Events
0
group Id
EG001
num Affected
2
num At Risk
388
num Events
2
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Leukopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
8
num At Risk
388
num Events
8
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
0
num At Risk
406
num Events
0
group Id
EG001
num Affected
1
num At Risk
388
num Events
1
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Neutrophilia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
0
num At Risk
388
num Events
0
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Pancytopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
1
num At Risk
388
num Events
1
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Thrombocytopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
0
num At Risk
388
num Events
0
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Thrombotic microangiopathy
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
2
num At Risk
406
num Events
2
group Id
EG001
num Affected
0
num At Risk
388
num Events
0
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Acute coronary syndrome
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
3
num At Risk
406
num Events
3
group Id
EG001
num Affected
0
num At Risk
388
num Events
0
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Acute myocardial infarction

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
115
num At Risk
406
num Events
171
group Id
EG001
num Affected
181
num At Risk
388
num Events
240
group Id
EG002
num Affected
1
num At Risk
21
num Events
1
group Id
EG003
num Affected
1
num At Risk
6
num Events
3
term
Anaemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
28
num At Risk
406
num Events
72
group Id
EG001
num Affected
50
num At Risk
388
num Events
89
group Id
EG002
num Affected
1
num At Risk
21
num Events
3
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Leukopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
26
num At Risk
406
num Events
61
group Id
EG001
num Affected
30
num At Risk
388
num Events
45
group Id
EG002
num Affected
2
num At Risk
21
num Events
5
group Id
EG003
num Affected
1
num At Risk
6
num Events
1
term
Lymphopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
38
num At Risk
406
num Events
106
group Id
EG001
num Affected
125
num At Risk
388
num Events
213
group Id
EG002
num Affected
1
num At Risk
21
num Events
3
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
46
num At Risk
406
num Events
66
group Id
EG001
num Affected
26
num At Risk
388
num Events
31
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
2
num At Risk
6
num Events
3
term
Thrombocytopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
46
num At Risk
406
num Events
50
group Id
EG001
num Affected
4
num At Risk
388
num Events
4
group Id
EG002
num Affected
1
num At Risk
21
num Events
1
group Id
EG003
num Affected
1
num At Risk
6
num Events
1
term
Hyperthyroidism
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
238
num At Risk
406
num Events
299
group Id
EG001
num Affected
3
num At Risk
388
num Events
3
group Id
EG002
num Affected
4
num At Risk
21
num Events
5
group Id
EG003
num Affected
4
num At Risk
6
num Events
4
term
Hypothyroidism
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
96
num At Risk
406
num Events
141
group Id
EG001
num Affected
52
num At Risk
388
num Events
58
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
1
num At Risk
6
num Events
1
term
Abdominal pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
57
num At Risk
406
num Events
75
group Id
EG001
num Affected
28
num At Risk
388
num Events
34
group Id
EG002
num Affected
3
num At Risk
21
num Events
3
group Id
EG003
num Affected
1
num At Risk
6
num Events
1
term
Abdominal pain upper
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
116
num At Risk
406
num Events
142
group Id
EG001
num Affected
95
num At Risk
388
num Events
119
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
2
num At Risk
6
num Events
2
term
Constipation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
223
num At Risk
406
num Events
686
group Id
EG001
num Affected
76
num At Risk
388
num Events
107
group Id
EG002
num Affected
4
num At Risk
21
num Events
5
group Id
EG003
num Affected
3
num At Risk
6
num Events
6
term
Diarrhoea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
43
num At Risk
406
num Events
51
group Id
EG001
num Affected
12
num At Risk
388
num Events
16
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Dry mouth

Complete source fields

description

event Groups

deaths Num Affected
317
deaths Num At Risk
406
description
Participants with Endometrial cancer (EC) received lenvatinib 20 milligrams (mg) orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study
id
EG000
other Num Affected
404
other Num At Risk
406
serious Num Affected
237
serious Num At Risk
406
title
First Course: Lenvatinib + Pembrolizumab
deaths Num Affected
362
deaths Num At Risk
388
description
Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
id
EG001
other Num Affected
379
other Num At Risk
388
serious Num Affected
121
serious Num At Risk
388
title
First Course: TPC Doxorubicin or Paclitaxel
deaths Num Affected
8
deaths Num At Risk
21
description
Eligible participants who completed the first course of up to 35 administrations of pembrolizumab (\~2 years) and lenvatinib (\~2years) or who had Stable disease (SD) or partial response (PR) or had attained complete response (CR), but experienced radiologic progression of disease (PD) initiated a second course of pembrolizumab and lenvatinib at investigators discretion at the same dose and schedule at lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle upto 17 cycles (upto \~1 year)
id
EG002
other Num Affected
20
other Num At Risk
21
serious Num Affected
4
serious Num At Risk
21
title
Second Course: Lenvatinib + Pembrolizumab
deaths Num Affected
1
deaths Num At Risk
6
description
Eligible participants who completed the first course of either doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle and eligible participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\^2 doxorubicin, a maximum dose of paclitaxel per standard of care or who had Stable disease (SD) or partial response (PR) or had attained complete response (CR), but experienced radiologic progression of disease (PD) initiated treatment with pembrolizumab and lenvatinib at investigators discretion at the same dose and schedule at lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle upto 17 cycles (upto \~1 year)
id
EG003
other Num Affected
6
other Num At Risk
6
serious Num Affected
1
serious Num At Risk
6
title
TPC Crossover

frequency Threshold

other Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
115
num At Risk
406
num Events
171
group Id
EG001
num Affected
181
num At Risk
388
num Events
240
group Id
EG002
num Affected
1
num At Risk
21
num Events
1
group Id
EG003
num Affected
1
num At Risk
6
num Events
3
term
Anaemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
28
num At Risk
406
num Events
72
group Id
EG001
num Affected
50
num At Risk
388
num Events
89
group Id
EG002
num Affected
1
num At Risk
21
num Events
3
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Leukopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
26
num At Risk
406
num Events
61
group Id
EG001
num Affected
30
num At Risk
388
num Events
45
group Id
EG002
num Affected
2
num At Risk
21
num Events
5
group Id
EG003
num Affected
1
num At Risk
6
num Events
1
term
Lymphopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
38
num At Risk
406
num Events
106
group Id
EG001
num Affected
125
num At Risk
388
num Events
213
group Id
EG002
num Affected
1
num At Risk
21
num Events
3
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
46
num At Risk
406
num Events
66
group Id
EG001
num Affected
26
num At Risk
388
num Events
31
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
2
num At Risk
6
num Events
3
term
Thrombocytopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
46
num At Risk
406
num Events
50
group Id
EG001
num Affected
4
num At Risk
388
num Events
4
group Id
EG002
num Affected
1
num At Risk
21
num Events
1
group Id
EG003
num Affected
1
num At Risk
6
num Events
1
term
Hyperthyroidism
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
238
num At Risk
406
num Events
299
group Id
EG001
num Affected
3
num At Risk
388
num Events
3
group Id
EG002
num Affected
4
num At Risk
21
num Events
5
group Id
EG003
num Affected
4
num At Risk
6
num Events
4
term
Hypothyroidism
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
96
num At Risk
406
num Events
141
group Id
EG001
num Affected
52
num At Risk
388
num Events
58
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
1
num At Risk
6
num Events
1
term
Abdominal pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
57
num At Risk
406
num Events
75
group Id
EG001
num Affected
28
num At Risk
388
num Events
34
group Id
EG002
num Affected
3
num At Risk
21
num Events
3
group Id
EG003
num Affected
1
num At Risk
6
num Events
1
term
Abdominal pain upper
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
116
num At Risk
406
num Events
142
group Id
EG001
num Affected
95
num At Risk
388
num Events
119
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
2
num At Risk
6
num Events
2
term
Constipation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
223
num At Risk
406
num Events
686
group Id
EG001
num Affected
76
num At Risk
388
num Events
107
group Id
EG002
num Affected
4
num At Risk
21
num Events
5
group Id
EG003
num Affected
3
num At Risk
6
num Events
6
term
Diarrhoea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
43
num At Risk
406
num Events
51
group Id
EG001
num Affected
12
num At Risk
388
num Events
16
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Dry mouth

serious Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
9
num At Risk
388
num Events
9
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Anaemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
0
num At Risk
406
num Events
0
group Id
EG001
num Affected
1
num At Risk
388
num Events
1
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Febrile bone marrow aplasia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
2
num At Risk
406
num Events
2
group Id
EG001
num Affected
16
num At Risk
388
num Events
17
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Febrile neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
0
num At Risk
406
num Events
0
group Id
EG001
num Affected
1
num At Risk
388
num Events
1
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Leukocytosis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
0
num At Risk
406
num Events
0
group Id
EG001
num Affected
2
num At Risk
388
num Events
2
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Leukopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
8
num At Risk
388
num Events
8
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
0
num At Risk
406
num Events
0
group Id
EG001
num Affected
1
num At Risk
388
num Events
1
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Neutrophilia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
0
num At Risk
388
num Events
0
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Pancytopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
1
num At Risk
388
num Events
1
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Thrombocytopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
1
num At Risk
406
num Events
1
group Id
EG001
num Affected
0
num At Risk
388
num Events
0
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Thrombotic microangiopathy
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
2
num At Risk
406
num Events
2
group Id
EG001
num Affected
0
num At Risk
388
num Events
0
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Acute coronary syndrome
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 27.1
stats
group Id
EG000
num Affected
3
num At Risk
406
num Events
3
group Id
EG001
num Affected
0
num At Risk
388
num Events
0
group Id
EG002
num Affected
0
num At Risk
21
num Events
0
group Id
EG003
num Affected
0
num At Risk
6
num Events
0
term
Acute myocardial infarction

time Frame

Up to approximately 79 months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice